Rosalin Mishra

Years Active: 2020-2022
Publications (10 Years): 6

University of Cincinnati

National Centre For Cell Science (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Cincinnati Jun 01 2015

United States

Postdoctoral Researcher :: Division of pharmaceutical Science

Education History

National Centre For Cell Science

India

PHD :: Department of Biotechnology,University of Pune,INDIA

Publications

Mary Kate Kilroy, Briley SoYoung Park, Wasim Feroz, Hima Patel, Rosalin Mishra, Joan T Garrett, Joan T Garrett
HER3 Alterations in Cancer and Potential Clinical Implications. Cancers 14 (24) (2022)
Mary Kate Kilroy, Briley SoYoung Park, Wasim Feroz, Hima Patel, Rosalin Mishra, Joan T Garrett, Joan T Garrett
HER3 Alterations in Cancer and Potential Clinical Implications. Cancers 14 (24) (2022)
Rosalin Mishra, Hima Patel, Joan T Garrett, Mary Kate Kilroy, Joan T Garrett
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. International journal of molecular sciences 22 (7) (2021)
Hima Patel, Rosalin Mishra, Nour Yacoub, Joan T Garrett, Mary Kate Kilroy, Joan T Garrett
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma. Cancers 13 (22) (2021)
Rosalin Mishra, Long Yuan, Hima Patel, Aniruddha S Karve, Haizhou Zhu, Aaron White, Samar Alanazi, Pankaj Desai, Edward J Merino, Joan T Garrett
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. International journal of molecular sciences 22 (4) (2021)
Long Yuan, Rosalin Mishra, Hima Patel, Samar Alanazi, Xin Wei, Zhijun Ma, Joan T Garrett
BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels. Cancers 12 (6) (2020)

Rosalin Mishra.css-eqlu8i{font-size:small;padding-left:4px;}